JP2025507678A5 - - Google Patents
Info
- Publication number
- JP2025507678A5 JP2025507678A5 JP2024550195A JP2024550195A JP2025507678A5 JP 2025507678 A5 JP2025507678 A5 JP 2025507678A5 JP 2024550195 A JP2024550195 A JP 2024550195A JP 2024550195 A JP2024550195 A JP 2024550195A JP 2025507678 A5 JP2025507678 A5 JP 2025507678A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally
- subject
- approximately
- administering
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263314968P | 2022-02-28 | 2022-02-28 | |
| US63/314,968 | 2022-02-28 | ||
| PCT/US2023/063352 WO2023164695A2 (en) | 2022-02-28 | 2023-02-27 | Bcma-targeted car-t cell therapy for multiple myeloma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025507678A JP2025507678A (ja) | 2025-03-21 |
| JP2025507678A5 true JP2025507678A5 (enExample) | 2026-04-28 |
Family
ID=87762032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024550195A Pending JP2025507678A (ja) | 2022-02-28 | 2023-02-27 | Ｂｃｍａを標的とする、多発性骨髄腫のためのｃａｒ－ｔ細胞療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230270786A1 (enExample) |
| EP (1) | EP4486372A2 (enExample) |
| JP (1) | JP2025507678A (enExample) |
| KR (1) | KR20240158888A (enExample) |
| CN (1) | CN118900698A (enExample) |
| AU (1) | AU2023223523A1 (enExample) |
| CA (1) | CA3252674A1 (enExample) |
| MX (1) | MX2024010527A (enExample) |
| WO (1) | WO2023164695A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114929747A (zh) | 2019-11-05 | 2022-08-19 | 詹森生物科技公司 | 多发性骨髓瘤的靶向bcma的car-t细胞疗法 |
| GR1010884B (el) * | 2023-08-30 | 2025-02-19 | Janssen Biotech, Inc., | Θεραπεια τ κυτταρων με χιμαιρικο υποδοχεα αντιγονου (car) με στοχευμενο αντιγονο ωριμανσης των β κυτταρων (bcma) για πολλαπλο μυελωμα |
| WO2025170902A1 (en) * | 2024-02-05 | 2025-08-14 | Legend Biotech Usa Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
| WO2025171383A2 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens and related methods and uses |
| WO2025171388A1 (en) | 2024-02-09 | 2025-08-14 | Dispatch Biotherapeutics, Inc. | Engineered cancer antigens with modified domains and related methods and uses |
| US20250339527A1 (en) * | 2024-03-12 | 2025-11-06 | Legend Biotech Usa Inc. | Bcma-targeted car-t cell therapy for multiple myeloma |
| WO2026072671A1 (en) | 2024-09-24 | 2026-04-02 | City Of Hope | Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO1992008796A1 (en) | 1990-11-13 | 1992-05-29 | Immunex Corporation | Bifunctional selectable fusion genes |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5814618A (en) | 1993-06-14 | 1998-09-29 | Basf Aktiengesellschaft | Methods for regulating gene expression |
| US5464758A (en) | 1993-06-14 | 1995-11-07 | Gossen; Manfred | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5885827A (en) | 1996-01-23 | 1999-03-23 | The Regents Of The Universtiy Of California | Eukaryotic high rate mutagenesis system |
| FR2814642B1 (fr) | 2000-10-03 | 2005-07-01 | Ass Pour Le Dev De La Rech En | Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee |
| NZ579010A (en) | 2007-02-20 | 2012-03-30 | Anaptysbio Inc | Somatic hypermutation systems |
| CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| KR102512934B1 (ko) | 2016-08-10 | 2023-03-23 | 레전드 바이오테크 아일랜드 리미티드 | Bcma를 표적으로 하는 키메라 항원 수용체 및 이들의 이용 방법 |
-
2023
- 2023-02-27 US US18/175,347 patent/US20230270786A1/en active Pending
- 2023-02-27 AU AU2023223523A patent/AU2023223523A1/en active Pending
- 2023-02-27 EP EP23714942.2A patent/EP4486372A2/en active Pending
- 2023-02-27 JP JP2024550195A patent/JP2025507678A/ja active Pending
- 2023-02-27 KR KR1020247028096A patent/KR20240158888A/ko active Pending
- 2023-02-27 CN CN202380022977.0A patent/CN118900698A/zh active Pending
- 2023-02-27 CA CA3252674A patent/CA3252674A1/en active Pending
- 2023-02-27 WO PCT/US2023/063352 patent/WO2023164695A2/en not_active Ceased
-
2024
- 2024-08-27 MX MX2024010527A patent/MX2024010527A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240417455A1 (en) | Treatment for rheumatoid arthritis | |
| CN114245807A (zh) | Flt3l-fc融合蛋白和使用方法 | |
| JP2021512608A5 (enExample) | ||
| JP2022120009A (ja) | ベンラリツマブを使用して喘息の増悪率を低減する方法 | |
| JP2021514945A5 (enExample) | ||
| CN104010656B (zh) | 使用免疫球蛋白和c1-抑制剂的联合疗法 | |
| CA3098103A1 (en) | Molecular adjuvant | |
| JP2022535062A (ja) | Ｇｍ－ｃｓｆ拮抗薬を用いたがんの治療 | |
| JP2022514561A5 (enExample) | ||
| JP2024535431A5 (enExample) | ||
| EP3362088B1 (en) | An agent capable of depleting cd8 t cells for the treatment of myocardial infarction or acute myocardial infarction | |
| JP2023546504A5 (enExample) | ||
| Choi et al. | 2′-5′ oligoadenylate synthetase-like 1 (OASL1) deficiency suppresses central nervous system damage in a murine MOG-induced multiple sclerosis model | |
| JP2025526402A5 (enExample) | ||
| JP2024518410A5 (enExample) | ||
| JP2023551733A (ja) | 癌治療におけるｉｌ－１５及びｃｄ４０アゴニストの併用免疫療法 | |
| US20260053892A1 (en) | Induction and Expansion of Regulatory T Cells | |
| TW202540166A (zh) | 用於治療自體免疫性疾病／自體免疫性病症的ｃｄ１９選擇性ｔ細胞接合分子 | |
| TW202517679A (zh) | 以抗ｉｌｔ２抗體治療癌症 | |
| JP7132256B2 (ja) | 関節リウマチの治療 | |
| WO2026035942A1 (en) | Combinatorial therapy for alzheimer's disease | |
| JPS5821624A (ja) | 慢性関節リウマチの治療剤 | |
| Comi et al. | Immunoglobulins in chronic inflammatory demyelinating polyneuropathy | |
| JP2020515542A (ja) | Ｃｘｃｒ４／ｃｘｃｒ７の遮断およびヒトパピローマウイルス関連疾患の治療 | |
| CN118987233A (zh) | 治疗经典型霍奇金淋巴瘤的药物组合物及其用途 |